TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
Division of General Surgery
National Taiwan University Cancer Center
(在職)
Division of General Internal Medicine
Division of Hematology & Oncology
更新時間：2025-03-10
鄭安理Cheng, Ann-Lii
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
48Publications
21
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. PMID: 32161368; PMCID: PMC7188670.
22
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. PMID: 31790344.
23
Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, López López C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2020 Jan;9(1):93-104. doi: 10.1159/000504624. Epub 2019 Dec 16. PMID: 32071913; PMCID: PMC7024884.
24
Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2020 Feb;38(1):99-110. doi: 10.1007/s10637-019-00745-z. Epub 2019 Mar 2. PMID: 30825104; PMCID: PMC6985061.
25
Yang WC, Hsu FM, Chen YH, Shih JY, Yu CJ, Lin ZZ, Lu SH, Yang JC, Cheng AL, Kuo SH. Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clin Transl Radiat Oncol. 2020 Mar 23;22:76-82. doi: 10.1016/j.ctro.2020.03.008. PMID: 32280792; PMCID: PMC7139144.
26
Shen YC, Hsu CL, Jeng YM, Ho MC, Ho CM, Yeh CP, Yeh CY, Hsu MC, Hu RH, Cheng AL. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. J Hepatol. 2020 Mar;72(3):489-497. doi: 10.1016/j.jhep.2019.09.032. Epub 2019 Oct 18. PMID: 31634533.
27
Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025. PMID: 31954494.
28
Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol. 2020 Feb;72(2):209-214. doi: 10.1016/j.jhep.2019.11.006. PMID: 31954486.
29
Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. J Formos Med Assoc. 2020 Jan;119(1 Pt 2):335-344. doi: 10.1016/j.jfma.2019.05.027. Epub 2019 Jun 22. PMID: 31235201.
30
Chen CH, Lu YS, Cheng AL, Huang CS, Kuo WH, Wang MY, Chao M, Chen IC, Kuo CW, Lu TP, Lin CH. Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. Oncologist. 2020 Jan;25(1):e16-e23. doi: 10.1634/theoncologist.2019-0123. Epub 2019 Aug 1. PMID: 31371522; PMCID: PMC6964121.
